Results 121 to 130 of about 15,755 (201)

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]

, 2019
Lenihan, Daniel J, Stockerl-Goldstein, Keith E, Zhang, Kathleen W   +2 more
core   +1 more source

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial. [PDF]

EClinicalMedicine
Chen Y, Hua Z, Xu Y, Chen J, Wen Q, Sun T, Li H, Liu X, Fu R, Ju M, Xue F, Liu W, Dong H, Gu W, Dai X, Wang W, Chi Y, Pei X, Yang R, Zhang L.   +19 more
europepmc   +1 more source

Real-World Progression-Free Survival and Healthcare Resource Utilization Associated with Daratumumab Use in Transplant-Ineligible Multiple Myeloma Patients in Italy. [PDF]

Clinicoecon Outcomes Res
Perrone V, Barilà G, Franceschini L, Mele G, Mazzoni S, Cappuccilli M, Andretta M, Bacca M, Bartolini F, Barbieri A, Blasi A, Chinellato A, Dell'Orco S, Ferrante F, Lombardi R, Mancini D, Pagliaro R, Paciello A, Pastorello M, Procacci C, Ricciardulli D, Ubertazzo L, Valpondi P, Zucchi A, Degli Esposti L.   +24 more
europepmc   +1 more source

Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents. [PDF]

World J Methodol
Alam F, Siddiqui H, Nihal A, Andleeb M, Zaman AQU, Khushk MI, Hussain F, Rai R, Fatima FB, Kumar D, Rizvi SAFA, Jabeen S, Jawed I, Qadir U, Zakeri MA.   +14 more
europepmc   +1 more source

Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report. [PDF]

EJHaem
Marcolongo D, Bressan A, Zanatta E, Alaibac MSA, Gianesello I, Binotto G, Pavan L, Tos APD, Trentin L, Vianello F.   +9 more
europepmc   +1 more source

Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation. [PDF]

Blood Neoplasia
Davis JA, McElwee J, Gonzalez R, Julian K, Nachar VR, Snyder J, Mahmoudjafari Z, Granger K, Warrick M, Smith D, Baek G, Huang I, Portuguese A, Dima D, Banerjee R, Atrash S, Sborov DW, Grajales-Cruz A, Puglianini OC, Dominick A, Hansen DK, Elsey G, Moore DC.   +22 more
europepmc   +1 more source

Natural Killer Cells in Cancer Immunotherapy [PDF]

, 2019
Arndt MA, Chester C, Cortez VS, D'Andrea A, Elsasser D, Ferrini S, Gao Y, Hartmann F, Lotze MT, Miller JS, Orr MT, Seillet C, Soiffer RJ, Soto EO, Weiner LM, Yron I   +15 more
core   +1 more source

Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab. [PDF]

Discov Med (Singap)
Subramanian NG, Aung FM, Hunzeker ZE, Patel KK, Lee HC, Jin S, Young E, Bassett RL, Rojas Hernandez CM.   +8 more
europepmc   +1 more source

Evaluation of the reporting quality of randomized controlled trials for treatments in multiple myeloma published the last 5 years using the CONSORT 2010 statment [PDF]

, 2016
Ντέλλας, Παναγιώτης
core   +1 more source

MajesTEC-3: Redefining what's possible in multiple myeloma. [PDF]

Clin Hematol Int
Al Hadidi S, Gaballa M.
europepmc   +1 more source